|
|
|
|
|||||
|
|
|
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:
Webcasts of the fireside chats at the Leerink, Citizens and Barclays conferences will be available via the Events section of the Altimmune website.
Registered investors may request meetings on the dates noted above via their sales contacts at the respective banks.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
[email protected]
Media Contact:
Real Chemistry
[email protected]
This press release was published by a CLEAR® Verified individual.
| 3 hours | |
| Feb-26 | |
| Feb-17 | |
| Feb-02 | |
| Jan-29 | |
| Jan-29 | |
| Jan-28 | |
| Jan-27 | |
| Jan-23 | |
| Jan-23 | |
| Jan-06 | |
| Jan-05 | |
| Dec-29 | |
| Dec-19 | |
| Dec-11 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite